Texas Capital Bank Wealth Management Services Inc Makes New Investment in Astrazeneca Plc $AZN

Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,416 shares of the company’s stock, valued at approximately $600,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of AZN. Cibc World Market Inc. boosted its holdings in Astrazeneca by 21.5% in the third quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock valued at $4,942,000 after purchasing an additional 11,398 shares in the last quarter. TD Asset Management Inc boosted its holdings in Astrazeneca by 20.0% in the third quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock valued at $83,595,000 after purchasing an additional 181,273 shares in the last quarter. AMG National Trust Bank boosted its holdings in Astrazeneca by 20.4% in the third quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock valued at $3,298,000 after purchasing an additional 7,289 shares in the last quarter. Assetmark Inc. boosted its holdings in Astrazeneca by 6.5% in the third quarter. Assetmark Inc. now owns 310,383 shares of the company’s stock valued at $23,813,000 after purchasing an additional 19,020 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in Astrazeneca by 6.6% in the third quarter. US Bancorp DE now owns 242,181 shares of the company’s stock valued at $18,581,000 after purchasing an additional 15,065 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Price Performance

Shares of NYSE AZN opened at $185.66 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The stock has a 50 day moving average of $191.34 and a two-hundred day moving average of $183.64. The stock has a market cap of $287.94 billion, a P/E ratio of 27.88, a P/E/G ratio of 1.48 and a beta of 0.26.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. On average, research analysts forecast that Astrazeneca Plc will post 10.26 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, May 13th. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Finally, Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.